Study explorer (study characteristics and results) method abbreviations pdf   xlsx

display ongoing studies
Study Ref. studied treatmentcontrol treatmentpatientsstudy risk of biassample sizes Results deaths Eclinical improvement Edeath or ventilation E

COVID 19 hospitalized meta-analysis

Entrenas (Pilot Calcifediol), 2020
RCTVitamin Dstandard of careCOVID 19 hospitalizedsome concern
50/26 conclusif -79%
Annweiler (GERIA-COVID; regular intake of bolus vitamin D), 2020 OBSVitamin DcontrolCOVID 19 hospitalizedNA
29/32 suggested -84% -83%
Annweiler (GERIA-COVID; Vitamin D Supplementation After COVID-19 Diagnosis), 2020 OBSVitamin DcontrolCOVID 19 hospitalizedNA
16/32 inconclusive -57% -49%

COVID-19 mild to moderate meta-analysis

Rastogi, 2020
RCTVitamin DplaceboCOVID-19 mild to moderateNA
16/24 suggested
Espitia-Hernandez, 2020 NRaVitamin Dstandard of careCOVID 19 outpatients, COVID-19 mild to moderateNA
28/7 suggested

COVID-19 severe or critically meta-analysis

Murai, 2020
RCTVitamin DplaceboCOVID-19 severe or criticallysome concern
120/120 inconclusive 32%

PE: primary endpoint; (a): to be demonstrated a result must be statistically significant on a primary endpoint (with multiplicity adjustment if necessary);
Study risk of bias assessed for the study primary endpoint(s) or the main endpoints in case of no formally defined primary endpoint(s).